Rebound hypersecretion of GH following octreotide withdrawal due to liver dysfunction in an acromegalic patient.
Octreotide usually induces long-acting inhibition of GH secretion without rebound hypersecretion. We report a patient with acromegaly who showed rebound elevation of GH and insulin-like growth factor-1 (IGF-1) after octreotide withdrawal. The patient responded remarkably to octreotide therapy with normalization of GH and IGF-1 and shrinkage of pituitary macroadenoma. Octreotide therapy was stopped when he developed liver dysfunction. GH and IGF-1 were markedly elevated for two weeks after cessation of octreotide.
Shimatsu
A
A
Clinical Research Institute, Kyoto National Hospital, Japan.
Murabe
H
H
Nakamura
Y
Y
Usui
T
T
D000172:Acromegaly / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006728:Hormones / Q000627:therapeutic use*; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*
D006728:Hormones; D019382:Human Growth Hormone; D015282:Octreotide